Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Clin Pharmacol Ther 26:483492 Sotaniemi EA, Pelkonen RO, Puukka M (1980) Measurement of hepatic drug-metabolizing enzyme activity in man
The efficacy question no press release answers: Oral small molecules historically trail injectable biologics on PASI response
ELISAs ELISA assays were performed in 96-well NUNC plates (Fisher Scientific 11371605) unless otherwise indicated
The phase 3 TRIUMPH-4 data showed these rates at 9 mg and 12 mg doses respectively: Nausea: 38.1% and 43.2% (vs 10.7% placebo) Diarrhea: 34.7% and 33.1% (vs 13.4% placebo) Constipation: 21.8% and 25.0% (vs 8.7% placebo) Vomiting: 20.4% and 20.9% (vs placebo) These numbers are higher than cagrilintide monotherapy across the board
US$ 28.50
US$ 28.31
US$ 20.80
US$ 25.56
